Advertisement

Topics

Epygenix’s EPX-300 Receives Orphan Drug Designation from the FDA for Treatment of Dravet Syndrome

09:25 EDT 23 Aug 2017 | Speciality Pharma Journal

PARAMUS, N.J., Aug. 23, 2017 /PRNewswire/ — Epygenix Therapeutics, Inc., a privately held biopharmaceutical company developing precision medicine for rare and catastrophic forms of genetic epilepsy, announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation for EPX-300 for the treatment of patients with Dravet Syndrome. Dravet Syndrome qualifies as a …

Original Article: Epygenix’s EPX-300 Receives Orphan Drug Designation from the FDA for Treatment of Dravet Syndrome

NEXT ARTICLE

More From BioPortfolio on "Epygenix’s EPX-300 Receives Orphan Drug Designation from the FDA for Treatment of Dravet Syndrome"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...